deltatrials
Terminated PHASE4 NCT00390975

Effect of Tegaserod on Gastric Emptying in Patients With Diabetic Gastroparesis

An Open-label Pilot Trial to Assess the Effect of Tegaserod on Improvement of Gastric Emptying in Patients With Diabetic Gastroparesis and Upper Gastrointestinal Symptoms

Sponsor: Novartis

Conditions Diabetes Gastroparesis
Interventions Tegaserod
Updated 9 times since 2017 Last updated: May 3, 2012 Started: Jan 31, 2007 Primary completion: Mar 31, 2007 Completion: Mar 31, 2007

This PHASE4 trial investigates Diabetes and Gastroparesis and is currently terminated or withdrawn. Novartis leads this study, which shows 9 recorded versions since 2007 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

9 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE4

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE4

  3. Dec 2021 — Jul 2024 [monthly]

    Terminated PHASE4

  4. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE4

  5. Nov 2020 — Jan 2021 [monthly]

    Terminated PHASE4

▶ Show 4 earlier versions

  1. Jun 2018 — Nov 2020 [monthly]

    Terminated PHASE4

  2. May 2018 — Jun 2018 [monthly]

    Terminated PHASE4

  3. Aug 2017 — May 2018 [monthly]

    Terminated PHASE4

  4. Jan 2017 — Aug 2017 [monthly]

    Terminated PHASE4

    First recorded

Jan 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Novartis
Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Boston, United States
  • • Kansas City, United States
  • • Louisville, United States